+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Sterile Injectable Drugs Market by Type, Drug Class, Administration Route, Dosage Form, Therapeutic Application, Distribution Channel - Global Forecast to 2030

  • PDF Icon

    Report

  • 183 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6012135
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Sterile Injectable Drugs Market grew from USD 550.55 billion in 2024 to USD 592.97 billion in 2025. It is expected to continue growing at a CAGR of 7.64%, reaching USD 856.50 billion by 2030.

Shaping the Future of Sterile Injectable Therapies

Sterile injectable therapies have redefined patient care by enabling targeted delivery of complex molecules directly into systemic circulation. The convergence of biotechnological advances and heightened demand for precision medicines has elevated these formulations to a pivotal role in managing chronic diseases, rare disorders, and acute interventions. In recent years, the industry has witnessed a surge in biologics that require stringent manufacturing standards, driving investments in state-of-the-art cleanroom facilities and advanced sterilization protocols.

As healthcare systems worldwide strive for efficiency and safety, the reliance on single-dose and multi-dose vials, pre-filled syringes, and autoinjectors has intensified. This trend underscores the importance of scalable production and robust supply chains. Meanwhile, regulatory bodies have tightened oversight, reinforcing the imperatives of process validation, contamination control, and rigorous quality assurance. Against this backdrop of technical complexity and regulatory rigor, a comprehensive understanding of market dynamics becomes essential for stakeholders seeking to capitalize on emerging opportunities.

This executive summary synthesizes the most salient developments shaping the sterile injectable space. Drawing on a wide array of primary interviews, expert analyses, and industry data, it offers decision-makers a clear view of transformative inflection points, tariff implications, segmentation nuances, regional variances, and strategic company profiles. By distilling these elements into actionable insights, this overview provides the strategic foundation needed to navigate an evolving and increasingly competitive landscape.

Emerging Catalysts Driving Industry Transformation

The sterile injectable realm is undergoing rapid metamorphosis as technological breakthroughs and shifting market demands converge. Continuous manufacturing platforms have emerged as a game-changer, enabling real-time monitoring and greater throughput, which is especially critical for biologics production. Simultaneously, single-use technologies are gaining prominence, reducing cross-contamination risks and shortening changeover cycles. These innovations not only streamline operations but also empower smaller contract manufacturing organizations to compete effectively against established incumbents.

At the same time, the advent of advanced analytics and artificial intelligence is transforming quality control paradigms. Predictive models now anticipate potential deviations in sterility or potency, allowing proactive interventions that minimize batch failures. This digital shift is complemented by modular cleanroom architectures that facilitate rapid expansion, supporting flexible production scales aligned with fluctuating demand.

Moreover, stakeholders are exploring novel container closure systems and parenteral delivery devices to enhance patient convenience and adherence. Custom pre-filled syringes with integrated safety features are reshaping outpatient and home-care settings. Coupled with growing emphasis on cold chain integrity and serialization, these advancements are elevating product security and traceability.

Collectively, these transformative catalysts are redefining competitive boundaries, challenging companies to align operational agility with uncompromising quality standards and to anticipate future regulatory expectations.

Assessing the Cumulative Impact of US Tariffs Enacted in 2025

In 2025, a series of additional tariffs on select pharmaceutical imports imposed by the United States has exerted discernible pressure on sterile injectable supply chains. Manufacturers that previously relied on cost-effective sourcing channels for key excipients and disposable components have had to reassess procurement strategies in light of escalating import duties. These tariffs have manifested in increased manufacturing overheads, compelling firms to explore alternative supplier relationships and re-engineer formulations to maintain margin thresholds.

The cumulative financial burden of these duties has prompted a shift toward nearshoring initiatives, with several organizations investing in domestic capacity expansions to mitigate exposure. While this strategic pivot demands significant capital deployment, it offers the promise of shorter lead times, reduced freight complexities, and enhanced supply chain visibility. At the same time, premium pricing for certain injectable products has surfaced, reflecting the pass-through of elevated costs to healthcare providers and payers.

Beyond cost implications, the tariff environment has catalyzed renewed dialogues with regulatory authorities to expedite local approval pathways for essential sterile formulations. Collaborative frameworks seeking to harmonize standards and facilitate mutual recognition agreements are gaining traction, offering a potential route to alleviate regulatory redundancies and speed product launches.

By proactively adapting sourcing blueprints and fostering government partnerships, stakeholders are positioning themselves to navigate the evolving tariff landscape while safeguarding patient access to critical injectable therapies.

Unveiling Critical Market Segmentation Dynamics

A multifaceted segmentation lens reveals the subtle forces shaping demand and driving strategic priorities across the sterile injectable market. In the realm of molecule classification, large proteins and antibody-based therapies continue to command a premium share due to their targeted mechanisms and favorable therapeutic indices, while small molecule injectables maintain steady uptake in emergency and acute care settings because of established delivery practices and cost advantages.

Diving deeper into therapeutic categories underscores varying growth dynamics. Blood factors and immunoglobulins are ascending in response to widening indications and prophylactic applications, whereas oncology agents, particularly monoclonal antibodies and peptide hormones, benefit from an expanding pipeline of personalized treatments. The diabetes segment, anchored by insulin analogs and biosimilars, remains a stalwart driver of volume, even as metabolic disorder portfolios broaden to address obesity.

Administration routes further elucidate evolving patient and provider preferences. Intravenous infusions retain dominance within hospital and clinic environments, but subcutaneous self-administration devices are gaining momentum for chronic therapies, offering both convenience and reduced healthcare resource utilization. Intramuscular and intradermal approaches find niche utilization in vaccines and adjuvant therapies, reflecting the importance of immunization programs and dermatological interventions.

Evaluating dosage form nuances reveals a growing tilt toward single-dose formats, especially pre-filled syringes that streamline dosing accuracy and reduce contamination risks. Nonetheless, multi-dose vials remain integral for high-volume hospital procurement. Finally, distribution pathways illustrate the expanding footprint of e-commerce platforms, which complement traditional hospital pharmacy orders and retail pharmacy dispensing by enabling direct-to-patient fulfillment in select regions.

Regional Market Nuances Across Key Geographies

Regional analyses highlight distinct market trajectories shaped by regulatory environments, healthcare infrastructure, and demographic trends. Within the Americas, advanced manufacturing ecosystems and robust reimbursement frameworks underpin broad adoption of high-value biologics, while strategic collaborations between industry and federal agencies are advancing domestic sterile fill-finish capabilities. This region’s emphasis on biosimilar approvals and value-based procurement is introducing cost efficiencies without compromising patient access.

In Europe, Middle East & Africa, heterogeneous regulatory regimes and varied economic landscapes create both challenges and opportunities. Western Europe’s stringent quality standards encourage investment in next-generation containment systems, whereas emerging markets in the Middle East and Africa are catalyzing demand through public health initiatives, particularly for vaccines and emergency injectables. Distribution complexity in this expanse necessitates resilient cold chain infrastructures and partnerships with local players to ensure last-mile delivery.

Asia-Pacific continues to represent the fastest-growing revenue pool, driven by expanding healthcare budgets, burgeoning patient populations, and policy mandates that prioritize domestic manufacturing. Countries such as China and India are scaling up contract manufacturing capacity, tapping into their low-cost labor markets while accelerating technology transfers. Concurrently, Japan and Australia maintain high per-capita consumption of premium injectable therapies, anchored by mature healthcare systems and a focus on chronic disease management.

Strategic Moves by Leading Sterile Injectable Innovators

Leading stakeholders in the sterile injectable domain are deploying diverse strategies to secure competitive advantage and fuel growth. Some multinational corporations are augmenting their portfolios through targeted acquisitions of specialized contract fill-finish providers, thereby enhancing end-to-end capabilities and geographic reach. Others are forging co-development alliances with biotech innovators to accelerate the commercialization of novel biologics, leveraging complementary expertise in formulation science and clinical development.

Parallel investments in digital infrastructure underscore a collective shift toward Industry 4.0 paradigms. Several organizations have integrated real-time process analytical technologies to monitor critical quality attributes during aseptic processing, resulting in elevated batch release efficiency and reduced inspection times. Meanwhile, strategic partnerships with technology firms are yielding advanced serialization and track-and-trace solutions that address regulatory imperatives and combat counterfeiting.

Beyond operational enhancements, major players are prioritizing sustainability by optimizing water usage, reducing energy footprints, and embracing single-use systems that minimize cleaning validation cycles. Initiatives to implement eco-friendly materials for primary packaging and secondary containment further reflect corporate commitments to environmental stewardship.

By aligning R&D pipelines with emerging therapeutic trends, investing in advanced manufacturing platforms, and pursuing strategic collaborations, these industry frontrunners are setting a foundational blueprint for sustained leadership in the sterile injectable sector.

Tactical Roadmap for Industry Stakeholders

To thrive in this complex landscape, industry leaders must adopt a proactive stance across multiple dimensions. First, integrating continuous manufacturing capabilities with modular plant designs will enable scalable responses to demand fluctuations and support rapid product introduction. Process intensification strategies, such as high-yield bioreactors and single-use perfusion systems, can further drive efficiency and cost containment.

Second, cultivating resilient supply networks is essential. By diversifying supplier bases for critical raw materials and establishing localized partnerships, companies can mitigate geopolitical and tariff-driven disruptions. Digital supply chain platforms that provide end-to-end visibility-from active pharmaceutical ingredients to finished vial tracking-will enhance agility and risk management.

Third, strengthening regulatory engagement through early dialogue and joint pilot programs can facilitate accelerated approval pathways, particularly for innovative drug-device combinations. Collaborative frameworks with health authorities and standard-setting bodies will help shape consensus on emerging sterilization technologies and digital validation methods.

Finally, embracing patient-centric delivery formats and connected device ecosystems will unlock new value propositions. Integrating dose-tracking sensors and mobile health platforms into injectable systems can provide real-time adherence data, improving therapeutic outcomes while generating novel revenue streams for service-based offerings.

Robust Analytical Framework Underpinning Our Study

This study synthesizes qualitative and quantitative inputs obtained through a rigorous multi-step research approach. Primary interviews with senior executives, process engineers, and regulatory specialists provided firsthand perspectives on manufacturing trends, technological adoption, and market barriers. These dialogues were complemented by in-depth case evaluations of leading fill-finish facilities and network analyses of emerging contract manufacturers.

Secondary sources-including peer-reviewed journals, regulatory filings, patent databases, and industry whitepapers-were systematically reviewed to validate market drivers and technology trajectories. Competitive intelligence exercises mapped the strategic footprints of key participants, revealing investment patterns, pipeline synergies, and cross-border collaborations. Expert workshops convened thought leaders to refine scenario analyses and stress test assumptions related to tariff impacts and segmentation shifts.

Analytical frameworks such as process capability assessments, value chain mapping, and risk quantification models underpinned the interpretation of data. Triangulation techniques ensured consistency between disparate information streams, while sensitivity analyses highlighted the robustness of qualitative insights under varying market conditions. This comprehensive methodology yields a balanced, actionable view of the sterile injectable drugs market without reliance on speculative forecasts.

Converging Insights and Forward-Looking Perspectives

The sterile injectable drugs market stands at a critical juncture where technological innovation, regulatory evolution, and global trade complexities intersect. As continuous manufacturing and digital quality control reshape production paradigms, tariff dynamics and supply chain resilience emerge as pivotal determinants of competitive positioning. Segmentation analysis underscores that tailored strategies across molecule types, dosage forms, administration routes, therapeutic applications, and distribution channels are essential to capture differentiated growth pockets.

Regional disparities further highlight the need for market-specific approaches, with established markets focusing on premium biologics and emerging regions prioritizing access to essential injectables. Leading companies have demonstrated that strategic alliances, capacity expansions, and sustainability initiatives can deliver both operational efficiencies and brand differentiation.

In this environment of rapid change, industry stakeholders must align investment priorities with evolving patient needs, regulatory expectations, and geopolitical realities. By leveraging the insights presented in this executive summary, decision-makers can formulate agile roadmaps that balance innovation with pragmatic risk management. This holistic perspective provides a solid foundation for shaping the next wave of growth in sterile injectable therapies.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Type
    • Large Molecule
    • Small Molecule
  • Drug Class
    • Blood Factors
    • Chemotherapy Agents
    • Cytokines
    • Immunoglobulin
    • Insulin
    • Monoclonal Antibody
    • Peptide Antibiotics
    • Peptide Hormones
    • Small Molecule Antibiotics
    • Vaccines
  • Administration Route
    • Intradermal
    • Intramuscular
    • Intravenous
    • Subcutaneous
  • Dosage Form
    • Multi-Dose
    • Single Dose
      • Ampoules
      • Pre-filled Syringes
  • Therapeutic Application
    • Cardiology
      • Congestive Heart Failure
      • Hypertension
      • Myocardial Infarction
    • Hormonal Disorders
      • Adrenal Disorders
      • Thyroid Disorders
    • Infectious Diseases
      • Bacterial Infections
      • Fungal Infections
      • Viral Infections
    • Metabolic Disorders
      • Diabetes
      • Obesity
    • Neurological Disorders
      • Multiple Sclerosis
      • Parkinson's Disease
    • Oncology
      • Breast Cancer
      • Colorectal Cancer
      • Lung Cancer
  • Distribution Channel
    • E-commerce
    • Hospital Pharmacy
    • Retail Pharmacy
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Adare Pharma Solutions
  • Aenova Group
  • Almac Group
  • Avara Pharmaceutical Services, Inc.
  • Baxter International Inc.
  • Boehringer Ingelheim International GmbH
  • Catalent, Inc.
  • CordenPharma
  • Eli Lilly and Company
  • Evonik Industries AG
  • F. Hoffmann-La Roche Ltd
  • Famar Group
  • Fresenius Kabi AG
  • Grifols S.A.
  • Hikma Pharmaceuticals PLC
  • Jubilant Pharmova Limited
  • Nexus Pharmaceuticals, Inc.
  • Patheon by hermo Fisher Scientific Inc.
  • Pfizer Inc.
  • Recipharm AB
  • Serum Institute of India Pvt. Ltd.
  • Siegfried Holding AG

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Sterile Injectable Drugs Market, by Type
8.1. Introduction
8.2. Large Molecule
8.3. Small Molecule
9. Sterile Injectable Drugs Market, by Drug Class
9.1. Introduction
9.2. Blood Factors
9.3. Chemotherapy Agents
9.4. Cytokines
9.5. Immunoglobulin
9.6. Insulin
9.7. Monoclonal Antibody
9.8. Peptide Antibiotics
9.9. Peptide Hormones
9.10. Small Molecule Antibiotics
9.11. Vaccines
10. Sterile Injectable Drugs Market, by Administration Route
10.1. Introduction
10.2. Intradermal
10.3. Intramuscular
10.4. Intravenous
10.5. Subcutaneous
11. Sterile Injectable Drugs Market, by Dosage Form
11.1. Introduction
11.2. Multi-Dose
11.3. Single Dose
11.3.1. Ampoules
11.3.2. Pre-filled Syringes
12. Sterile Injectable Drugs Market, by Therapeutic Application
12.1. Introduction
12.2. Cardiology
12.2.1. Congestive Heart Failure
12.2.2. Hypertension
12.2.3. Myocardial Infarction
12.3. Hormonal Disorders
12.3.1. Adrenal Disorders
12.3.2. Thyroid Disorders
12.4. Infectious Diseases
12.4.1. Bacterial Infections
12.4.2. Fungal Infections
12.4.3. Viral Infections
12.5. Metabolic Disorders
12.5.1. Diabetes
12.5.2. Obesity
12.6. Neurological Disorders
12.6.1. Multiple Sclerosis
12.6.2. Parkinson's Disease
12.7. Oncology
12.7.1. Breast Cancer
12.7.2. Colorectal Cancer
12.7.3. Lung Cancer
13. Sterile Injectable Drugs Market, by Distribution Channel
13.1. Introduction
13.2. E-commerce
13.3. Hospital Pharmacy
13.4. Retail Pharmacy
14. Americas Sterile Injectable Drugs Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Sterile Injectable Drugs Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Sterile Injectable Drugs Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Adare Pharma Solutions
17.3.2. Aenova Group
17.3.3. Almac Group
17.3.4. Avara Pharmaceutical Services, Inc.
17.3.5. Baxter International Inc.
17.3.6. Boehringer Ingelheim International GmbH
17.3.7. Catalent, Inc.
17.3.8. CordenPharma
17.3.9. Eli Lilly and Company
17.3.10. Evonik Industries AG
17.3.11. F. Hoffmann-La Roche Ltd
17.3.12. Famar Group
17.3.13. Fresenius Kabi AG
17.3.14. Grifols S.A.
17.3.15. Hikma Pharmaceuticals PLC
17.3.16. Jubilant Pharmova Limited
17.3.17. Nexus Pharmaceuticals, Inc.
17.3.18. Patheon by hermo Fisher Scientific Inc.
17.3.19. Pfizer Inc.
17.3.20. Recipharm AB
17.3.21. Serum Institute of India Pvt. Ltd.
17.3.22. Siegfried Holding AG
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. STERILE INJECTABLE DRUGS MARKET MULTI-CURRENCY
FIGURE 2. STERILE INJECTABLE DRUGS MARKET MULTI-LANGUAGE
FIGURE 3. STERILE INJECTABLE DRUGS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 10. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 14. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2030 (%)
FIGURE 16. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 18. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS STERILE INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS STERILE INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES STERILE INJECTABLE DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES STERILE INJECTABLE DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA STERILE INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA STERILE INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC STERILE INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC STERILE INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. STERILE INJECTABLE DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. STERILE INJECTABLE DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. STERILE INJECTABLE DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY LARGE MOLECULE, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY BLOOD FACTORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY CYTOKINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY IMMUNOGLOBULIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY INSULIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY PEPTIDE ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY PEPTIDE HORMONES, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY SMALL MOLECULE ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY INTRADERMAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY MULTI-DOSE, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY SINGLE DOSE, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY AMPOULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY PRE-FILLED SYRINGES, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY SINGLE DOSE, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY CONGESTIVE HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY HYPERTENSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY MYOCARDIAL INFARCTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY HORMONAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY ADRENAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY THYROID DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY HORMONAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY FUNGAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY DIABETES, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY OBESITY, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY METABOLIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY E-COMMERCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS STERILE INJECTABLE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS STERILE INJECTABLE DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS STERILE INJECTABLE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS STERILE INJECTABLE DRUGS MARKET SIZE, BY SINGLE DOSE, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS STERILE INJECTABLE DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS STERILE INJECTABLE DRUGS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS STERILE INJECTABLE DRUGS MARKET SIZE, BY HORMONAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS STERILE INJECTABLE DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS STERILE INJECTABLE DRUGS MARKET SIZE, BY METABOLIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS STERILE INJECTABLE DRUGS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS STERILE INJECTABLE DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS STERILE INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES STERILE INJECTABLE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES STERILE INJECTABLE DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES STERILE INJECTABLE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES STERILE INJECTABLE DRUGS MARKET SIZE, BY SINGLE DOSE, 2018-2030 (USD MILLION)
TABLE 82. UNITED STATES STERILE INJECTABLE DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 83. UNITED STATES STERILE INJECTABLE DRUGS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 84. UNITED STATES STERILE INJECTABLE DRUGS MARKET SIZE, BY HORMONAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 85. UNITED STATES STERILE INJECTABLE DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 86. UNITED STATES STERILE INJECTABLE DRUGS MARKET SIZE, BY METABOLIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 87. UNITED STATES STERILE INJECTABLE DRUGS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 88. UNITED STATES STERILE INJECTABLE DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 89. UNITED STATES STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 90. UNITED STATES STERILE INJECTABLE DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 91. CANADA STERILE INJECTABLE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 92. CANADA STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 93. CANADA STERILE INJECTABLE DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 94. CANADA STERILE INJECTABLE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 95. CANADA STERILE INJECTABLE DRUGS MARKET SIZE, BY SINGLE DOSE, 2018-2030 (USD MILLION)
TABLE 96. CANADA STERILE INJECTABLE DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 97. CANADA STERILE INJECTABLE DRUGS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 98. CANADA STERILE INJECTABLE DRUGS MARKET SIZE, BY HORMONAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 99. CANADA STERILE INJECTABLE DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 100. CANADA STERILE INJECTABLE DRUGS MARKET SIZE, BY METABOLIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 101. CANADA STERILE INJECTABLE DRUGS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 102. CANADA STERILE INJECTABLE DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 103. CANADA STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 104. MEXICO STERILE INJECTABLE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 105. MEXICO STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 106. MEXICO STERILE INJECTABLE DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 107. MEXICO STERILE INJECTABLE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 108. MEXICO STERILE INJECTABLE DRUGS MARKET SIZE, BY SINGLE DOSE, 2018-2030 (USD MILLION)
TABLE 109. MEXICO STERILE INJECTABLE DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 110. MEXICO STERILE INJECTABLE DRUGS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 111. MEXICO STERILE INJECTABLE DRUGS MARKET SIZE, BY HORMONAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 112. MEXICO STERILE INJECTABLE DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 113. MEXICO STERILE INJECTABLE DRUGS MARKET SIZE, BY METABOLIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 114. MEXICO STERILE INJECTABLE DRUGS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 115. MEXICO STERILE INJECTABLE DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 116. MEXICO STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL STERILE INJECTABLE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 118. BRAZIL STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 119. BRAZIL STERILE INJECTABLE DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 120. BRAZIL STERILE INJECTABLE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 121. BRAZIL STERILE INJECTABLE DRUGS MARKET SIZE, BY SINGLE DOSE, 2018-2030 (USD MILLION)
TABLE 122. BRAZIL STERILE INJECTABLE DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 123. BRAZIL STERILE INJECTABLE DRUGS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 124. BRAZIL STERILE INJECTABLE DRUGS MARKET SIZE, BY HORMONAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 125. BRAZIL STERILE INJECTABLE DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 126. BRAZIL STERILE INJECTABLE DRUGS MARKET SIZE, BY METABOLIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 127. BRAZIL STERILE INJECTABLE DRUGS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 128. BRAZIL STERILE INJECTABLE DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 129. BRAZIL STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 130. ARGENTINA STERILE INJECTABLE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 131. ARGENTINA STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 132. ARGENTINA STERILE INJECTABLE DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 133. ARGENTINA STERILE INJECTABLE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 134. ARGENTINA STERILE INJECTABLE DRUGS MARKET SIZE, BY SINGLE DOSE, 2018-2030 (USD MILLION)
TABLE 135. ARGENTINA STERILE INJECTABLE DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 136. ARGENTINA STERILE INJECTABLE DRUGS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 137. ARGENTINA STERILE INJECTABLE DRUGS MARKET SIZE, BY HORMONAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 138. ARGENTINA STERILE INJECTABLE DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 139. ARGENTINA STERILE INJECTABLE DRUGS MARKET SIZE, BY METABOLIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 140. ARGENTINA STERILE INJECTABLE DRUGS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 141. ARGENTINA STERILE INJECTABLE DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 142. ARGENTINA STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA STERILE INJECTABLE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA STERILE INJECTABLE DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA STERILE INJECTABLE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA STERILE INJECTABLE DRUGS MARKET SIZE, BY SINGLE DOSE, 2018-2030 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA STERILE INJECTABLE DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA STERILE INJECTABLE DRUGS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA STERILE INJECTABLE DRUGS MARKET SIZE, BY HORMONAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA STERILE INJECTABLE DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA STERILE INJECTABLE DRUGS MARKET SIZE, BY METABOLIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA STERILE INJECTABLE DRUGS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA STERILE INJECTABLE DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA STERILE INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 157. UNITED KINGDOM STERILE INJECTABLE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 158. UNITED KINGDOM STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 159. UNITED KINGDOM STERILE INJECTABLE DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 160. UNITED KINGDOM STERILE INJECTABLE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 161. UNITED KINGDOM STERILE INJECTABLE DRUGS MARKET SIZE, BY SINGLE DOSE, 2018-2030 (USD MILLION)
TABLE 162. UNITED KINGDOM STERILE INJECTABLE DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 163. UNITED KINGDOM STERILE INJECTABLE DRUGS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 164. UNITED KINGDOM STERILE INJECTABLE DRUGS MARKET SIZE, BY HORMONAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 165. UNITED KINGDOM STERILE INJECTABLE DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 166. UNITED KINGDOM STERILE INJECTABLE DRUGS MARKET SIZE, BY METABOLIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 167. UNITED KINGDOM STERILE INJECTABLE DRUGS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 168. UNITED KINGDOM STERILE INJECTABLE DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 169. UNITED KINGDOM STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 170. GERMANY STERILE INJECTABLE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 171. GERMANY STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 172. GERMANY STERILE INJECTABLE DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 173. GERMANY STERILE INJECTABLE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 174. GERMANY STERILE INJECTABLE DRUGS MARKET SIZE, BY SINGLE DOSE, 2018-2030 (USD MILLION)
TABLE 175. GERMANY STERILE INJECTABLE DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 176. GERMANY STERILE INJECTABLE DRUGS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 177. GERMANY STERILE INJECTABLE DRUGS MARKET SIZE, BY HORMONAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 178. GERMANY STERILE INJECTABLE DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 179. GERMANY STERILE INJECTABLE DRUGS MARKET SIZE, BY METABOLIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 180. GERMANY STERILE INJECTABLE DRUGS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 181. GERMANY STERILE INJECTABLE DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 182. GERMANY STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 183. FRANCE STERILE INJECTABLE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 184. FRANCE STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 185. FRANCE STERILE INJECTABLE DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 186. FRANCE STERILE INJECTABLE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 187. FRANCE STERILE INJECTABLE DRUGS MARKET SIZE, BY SINGLE DOSE, 2018-2030 (USD MILLION)
TABLE 188. FRANCE STERILE INJECTABLE DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 189. FRANCE STERILE INJECTABLE DRUGS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 190. FRANCE STERILE INJECTABLE DRUGS MARKET SIZE, BY HORMONAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 191. FRANCE STERILE INJECTABLE DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 192. FRANCE STERILE INJECTABLE DRUGS MARKET SIZE, BY METABOLIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 193. FRANCE STERILE INJECTABLE DRUGS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 194. FRANCE STERILE INJECTABLE DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 195. FRANCE STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 196. RUSSIA STERILE INJECTABLE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 197. RUSSIA STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 198. RUSSIA STERILE INJECTABLE DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 199. RUSSIA STERILE INJECTABLE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 200. RUSSIA STERILE INJECTABLE DRUGS MARKET SIZE, BY SINGLE DOSE, 2018-2030 (USD MILLION)
TABLE 201. RUSSIA STERILE INJECTABLE DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 202. RUSSIA STERILE INJECTABLE DRUGS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 203. RUSSIA STERILE INJECTABLE DRUGS MARKET SIZE, BY HORMONAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 204. RUSSIA STERILE INJECTABLE DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 205. RUSSIA STERILE INJECTABLE DRUGS MARKET SIZE, BY METABOLIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 206. RUSSIA STERILE INJECTABLE DRUGS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 207. RUSSIA STERILE INJECTABLE DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 208. RUSSIA STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 209. ITALY STERILE INJECTABLE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 210. ITALY STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 211. ITALY STERILE INJECTABLE DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 212. ITALY STERILE INJECTABLE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 213. ITALY STERILE INJECTABLE DRUGS MARKET SIZE, BY SINGLE DOSE, 2018-2030 (USD MILLION)
TABLE 214. ITALY STERILE INJECTABLE DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 215. ITALY STERILE INJECTABLE DRUGS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 216. ITALY STERILE INJECTABLE DRUGS MARKET SIZE, BY HORMONAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 217. ITALY STERILE INJECTABLE DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 218. ITALY STERILE INJECTABLE DRUGS MARKET SIZE, BY METABOLIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 219. ITALY STERILE INJECTABLE DRUGS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 220. ITALY STERILE INJECTABLE DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 221. ITALY STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 222. SPAIN STERILE INJECTABLE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 223. SPAIN STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 224. SPAIN STERILE INJECTABLE DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 225. SPAIN STERILE INJECTABLE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 226. SPAIN STERILE INJECTABLE DRUGS MARKET SIZE, BY SINGLE DOSE, 2018-2030 (USD MILLION)
TABLE 227. SPAIN STERILE INJECTABLE DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 228. SPAIN STERILE INJECTABLE DRUGS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 229. SPAIN STERILE INJECTABLE DRUGS MARKET SIZE, BY HORMONAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 230. SPAIN STERILE INJECTABLE DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 231. SPAIN STERILE INJECTABLE DRUGS MARKET SIZE, BY METABOLIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 232. SPAIN STERILE INJECTABLE DRUGS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 233. SPAIN STERILE INJECTABLE DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 234. SPAIN STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 235. UNITED ARAB EMIRATES STERILE INJECTABLE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 236. UNITED ARAB EMIRATES STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 237. UNITED ARAB EMIRATES STERILE INJECTABLE DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 238. UNITED ARAB EMIRATES STERILE INJECTABLE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 239. UNITED ARAB EMIRATES STERILE INJECTABLE DRUGS MARKET SIZE, BY SINGLE DOSE, 2018-2030 (USD MILLION)
TABLE 240. UNITED ARAB EMIRATES STERILE INJECTABLE DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 241. UNITED ARAB EMIRATES STERILE INJECTABLE DRUGS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 242. UNITED ARAB EMIRATES STERILE INJECTABLE DRUGS MARKET SIZE, BY HORMONAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 243. UNITED ARAB EMIRATES STERILE INJECTABLE DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 244. UNITED ARAB EMIRATES STERILE INJECTABLE DRUGS MARKET SIZE, BY METABOLIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 245. UNITED ARAB EMIRATES STERILE INJECTABLE DRUGS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 246. UNITED ARAB EMIRATES STERILE INJECTABLE DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 247. UNITED ARAB EMIRATES STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 248. SAUDI ARABIA STERILE INJECTABLE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 249. SAUDI ARABIA STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 250. SAUDI ARABIA STERILE INJECTABLE DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 251. SAUDI ARABIA STERILE INJECTABLE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 252. SAUDI ARABIA STERILE INJECTABLE DRUGS MARKET SIZE, BY SINGLE DOSE, 2018-2030 (USD MILLION)
TABLE 253. SAUDI ARABIA STERILE INJECTABLE DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 254. SAUDI ARABIA STERILE INJECTABLE DRUGS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 255. SAUDI ARABIA STERILE INJECTABLE DRUGS MARKET SIZE, BY HORMONAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 256. SAUDI ARABIA STERILE INJECTABLE DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 257. SAUDI ARABIA STERILE INJECTABLE DRUGS MARKET SIZE, BY METABOLIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 258. SAUDI ARABIA STERILE INJECTABLE DRUGS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 259. SAUDI ARABIA STERILE INJECTABLE DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 260. SAUDI ARABIA STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 261. SOUTH AFRICA STERILE INJECTABLE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 262. SOUTH AFRICA STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 263. SOUTH AFRICA STERILE INJECTABLE DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 264. SOUTH AFRICA STERILE INJECTABLE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 265. SOUTH AFRICA STERILE INJECTABLE DRUGS MARKET SIZE, BY SINGLE DOSE, 2018-2030 (USD MILLION)
TABLE 266. SOUTH AFRICA STERILE INJECTABLE DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 267. SOUTH AFRICA STERILE INJECTABLE DRUGS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 268. SOUTH AFRICA STERILE INJECTABLE DRUGS MARKET SIZE, BY HORMONAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 269. SOUTH AFRICA STERILE INJECTABLE DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 270. SOUTH AFRICA STERILE INJECTABLE DRUGS MARKET SIZE, BY METABOLIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 271. SOUTH AFRICA STERILE INJECTABLE DRUGS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 272. SOUTH AFRICA STERILE INJECTABLE DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 273. SOUTH AFRICA STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 274. DENMARK STERILE INJECTABLE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 275. DENMARK STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 276. DENMARK STERILE INJECTABLE DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 277. DENMARK STERILE INJECTABLE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 278. DENMARK STERILE INJECTABLE DRUGS MARKET SIZE, BY SINGLE DOSE, 2018-2030 (USD MILLION)
TABLE 279. DENMARK STERILE INJECTABLE DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 280. DENMARK STERILE INJECTABLE DRUGS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 281. DENMARK STERILE INJECTABLE DRUGS MARKET SIZE, BY HORMONAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 282. DENMARK STERILE INJECTABLE DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 283. DENMARK STERILE INJECTABLE DRUGS MARKET SIZE, BY METABOLIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 284. DENMARK STERILE INJECTABLE DRUGS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 285. DENMARK STERILE INJECTABLE DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 286. DENMARK STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 287. NETHERLANDS STERILE INJECTABLE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 288. NETHERLANDS STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 289. NETHERLANDS STERILE INJECTABLE DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 290. NETHERLANDS STERILE INJECTABLE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 291. NETHERLANDS STERILE INJECTABLE DRUGS MARKET SIZE, BY SINGLE DOSE, 2018-2030 (USD MILLION)
TABLE 292. NETHERLANDS STERILE INJECTABLE DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 293. NETHERLANDS STERILE INJECTABLE DRUGS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 294. NETHERLANDS STERILE INJECTABLE DRUGS MARKET SIZE, BY HORMONAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 295. NETHERLANDS STERILE INJECTABLE DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 296. NETHERLANDS STERILE INJECTABLE DRUGS MARKET SIZE, BY METABOLIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 297. NETHERLANDS STERILE INJECTABLE DRUGS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 298. NETHERLANDS STERILE INJECTABLE DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 299. NETHERLANDS STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 300. QATAR STERILE INJECTABLE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 301. QATAR STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 302. QATAR STERILE INJECTABLE DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 303. QATAR STERILE INJECTABLE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 304. QATAR STERILE INJECTABLE DRUGS MARKET SIZE, BY SINGLE DOSE, 2018-2030 (USD MILLION)
TABLE 305. QATAR STERILE INJECTABLE DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 306. QATAR STERILE INJECTABLE DRUGS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 307. QATAR STERILE INJECTABLE DRUGS MARKET SIZE, BY HORMONAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 308. QATAR STERILE INJECTABLE DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 309. QATAR STERILE INJECTABLE DRUGS MARKET SIZE, BY METABOLIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 310. QATAR STERILE INJECTABLE DRUGS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 311. QATAR STERILE INJECTABLE DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 312. QATAR STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 313. FINLAND STERILE INJECTABLE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 314. FINLAND STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 315. FINLAND STERILE INJECTABLE DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 316. FINLAND STERILE INJECTABLE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-203

Companies Mentioned

The companies profiled in this Sterile Injectable Drugs market report include:
  • Adare Pharma Solutions
  • Aenova Group
  • Almac Group
  • Avara Pharmaceutical Services, Inc.
  • Baxter International Inc.
  • Boehringer Ingelheim International GmbH
  • Catalent, Inc.
  • CordenPharma
  • Eli Lilly and Company
  • Evonik Industries AG
  • F. Hoffmann-La Roche Ltd
  • Famar Group
  • Fresenius Kabi AG
  • Grifols S.A.
  • Hikma Pharmaceuticals PLC
  • Jubilant Pharmova Limited
  • Nexus Pharmaceuticals, Inc.
  • Patheon by hermo Fisher Scientific Inc.
  • Pfizer Inc.
  • Recipharm AB
  • Serum Institute of India Pvt. Ltd.
  • Siegfried Holding AG

Methodology

Loading
LOADING...

Table Information